NEW YORK, April 06, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (NASDAQ:INSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased INSYS securities between February 23, 2016 and March 15, 2017, both dates inclusive (the “Class Period"). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/insy.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) as a result, INSYS lacked effective internal controls over financial reporting; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On March 15, 2017, after-market hours, INSYS announced that it postponed filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that “[t]he Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016.” Following this news, INSYS stock dropped $0.49 per share, or 4.64%, to close at $10.06 on March 16, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/insy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 



